title: Genomic markers to tailor treatments: waiting or initiating?
abstract: The decade since the publication of the Human Genome Project draft has ended with the discovery of hundreds of genomic markers related to diseases and phenotypes. However, the project has not yet delivered on its promise to tailor treatments for individuals. The number of genomic markers in clinical practice is very small. The number of markers to guide treatment decisions is even smaller. In order to speed up discovery and validation of genomic treatment selection markers, we call for considering the brilliant potential of randomized clinical trials. If biomedical research community can collaborate in organizing large-scale consortium of clinical trials associated with well-designed biobanks, these studies would soon act as huge laboratories for investigating genomic medicine; a big step forward towards personalizing medicine.
authors.affiliation: Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. P.Tajik@amc.uva.nl
authors.forename: Parvin
authors.initials: P
authors.lastname: Tajik
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Bossuyt
mesh_terms: D018070:Biological Specimen Banks; D018390:Gene Targeting; D005819:Genetic Markers; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D005819:Genetic Markers